Saturday 17 October 2026
Export ROIV’s income statement to Excel — free account
Roivant Sciences Ltd.
ROIV Healthcare Biotechnology
In the quarter to June 2026, revenue fell 33.6%, EPS grew 21.2% and free cash flow fell 30.0%, each against the same quarter a year earlier.
33.53
0.51
−1.50%
Follow ROIV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 4 | 3 |
+8 more TTM periods Free account |
| (5.47%) | (5.72%) | (15.40%) | (7.20%) | ||
| (5.15%) | (5.38%) | (14.69%) | (6.64%) | ||
ROIC |
(34.51%) | (32.17%) | (170.97%) | (171.36%) | |
Return on Tangible Assets |
(5.96%) | (6.12%) | (17.90%) | (8.49%) | |
Average Days of Receivables |
37,392.97 | 34,035.81 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.14) | (1.09) | (1.10) | (1.15) | |
Free Cash Flow |
(821.06) | (758.56) | (766.85) | (784.38) | |
Capital Expenditures |
(4.59) | (8.21) | (7.76) | (14.52) | |
| Other line items | |||||
Cash ROIC |
(9.37%) | (7.91%) | (8.07%) | (8.53%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.08 | 0.06 | 0.06 | 0.04 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
6,470.43 | 5,113.41 | 4,147.27 | 7,542.33 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.43 | 0.50 | 0.09 | 0.04 | |
Research and Development Expense of Revenue |
9,704.05% | 8,254.38% | 4,719.05% | 2,972.70% | |
Selling, General and Administrative Expense of Revenue |
8,523.29% | 7,390.63% | 4,502.69% | 2,783.12% | |
Share Based Compensation of Revenue |
4,611.38% | 4,190.86% | 2,648.26% | 1,629.04% | |
Operating CF/Net income |
3.07 | 2.50 | 0.94 | 2.06 | |
Depreciation/Fixed assets |
0.25 | 0.28 | 0.31 | 0.25 | |
Capex/Depreciation |
(1.61) | (2.45) | (1.88) | (2.28) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.03 | |
Operating CF per Share |
(1.13) | (1.08) | (1.09) | (1.13) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.61 | 0.99 | 0.58 | 0.71 |
Columns are period end dates · fundamentals updated 1 Oct 2026